Traditionally, mitral regurgitation has only been treated by open heart surgery to either replace or repair the mitral valve. UVA is among the first in the country to offer a newer, less invasive treatment option — the MitraClip® procedure.
Are you Eligible?
The MitraClip is FDA approved for patients with degenerative mitral valve disease (leaking mitral valve due to abnormalities of the mitral valve, such as prolapse or flail leaflets).
Patients with functional mitral regurgitation (mitral valve leakage due to weak heart muscle from a prior heart attack) who have had previous surgical mitral valve repairs may be eligible for a clinical trial using MitraClip.
Those with mitral regurgitation due to rheumatic fever or prior infection are not candidates for this type of percutaneous mitral valve repair.
Advantages of MitraClip® Procedure
UVA is one of the first in the country to offer the MitraClip® procedure: a new, less invasive treatment alternative to open heart surgery.
Evaluation for MitraClip Procedure
Tests may include:
- Chest X-ray
- Cardiac catheterization
- Holter monitor
About the MitraClip Procedure
You are given general anesthesia prior to an ultrasound test called transesophageal echocardiogram.
Your doctor passes the ultrasound transducer through your mouth and down your esophagus to the stomach. This transducer stays in place, which allows your doctor to clearly see the mitral valve and help guide the MitraClip placement.
Your doctor uses a catheter to insert the MitraClip (a tiny metal device) through a small incision on the blood vessel in the leg and threads up to the heart. One or two MitraClip devices are placed on the leaking portions of the mitral valve, to repair the mitral regurgitation without the using open heart surgery.